Exact Sciences Corporation rose 1.44% in intraday trading, with RBC raising its price target on the company to $50 from a previous target. The company is a global advanced cancer diagnostics company, focusing on earlier cancer detection and treatment guidance. Its products and services include the Cologuard test, Oncotype DX Breast Recurrence Score Test, and other precision oncology tests.
Comments
No comments yet